Tag: MedImmune

AstraZeneca’s cancer drug shows positive result in NSCLC treatment
May 12, 2017 Off

AstraZeneca’s cancer drug shows positive result in NSCLC treatment

By Dino Mustafić

AstraZeneca and its subsidiary MedImmune, have reported positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.

AstraZeneca’s asthma drug study fails expectations
May 10, 2017 Off

AstraZeneca’s asthma drug study fails expectations

By Dino Mustafić

AstraZeneca and its subsidiary MedImmune have reported that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the first of two pivotal Phase III trials.

Sanofi, AstraZeneca making Respiratory Syncytial Virus vaccine
March 3, 2017 Off

Sanofi, AstraZeneca making Respiratory Syncytial Virus vaccine

By Dino Mustafić

Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).

February 17, 2016 Off

Durvalumab granted BTD by FDA for cancer patients

By Dino Mustafić

AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.